Compass leverages proprietary antibody discovery platforms including common light chain-focused discovery and human display technology to develop highly modular and manufacturable bispecific candidates. The company is strategically positioned in immuno-oncology through lead candidate tovecimig (targeting DLL4 and VEGF-A) with multiple Phase I/II programs advancing in solid tumors and hematologic malignancies.
Cyborg Score Rationale
Compass shows solid pipeline progress with tovecimig advancing toward efficacy readouts in Q1 2026 and multiple clinical programs underway, but faces typical clinical-stage biotech risks. Recent leadership additions (Chief Commercial and Medical Officers) signal commercialization readiness, though the company remains pre-revenue with cash-dependent financing needs.
Top Insights
Lead candidate tovecimig has generated early clinical signals in biliary tract cancers with Phase II ongoing and Phase Ib data in colorectal/ovarian cancers planned for late Q1 2026
Multi-pronged pipeline includes CTX-8371 (PD-1/PD-L1 bispecific) with responses in Hodgkin lymphoma and cohort expansions in TNBC/NSCLC, plus CTX-10726 (PD-1/VEGF-A) starting Phase 1 in Q1 2026
Recent executive hires (Chief Commercial Officer and Chief Medical Officer effective January 2026) include experienced oncology commercialization leadership from Servier, signaling preparation for late-stage development
Stock has appreciated 82% over the past year but remains volatile; analyst price targets range from $8-$30 with mixed sentiment suggesting meaningful clinical readout dependency
Named Competitors
Immuno-oncology therapeutics — Large pharma competitors with established checkpoint inhibitor portfolios
(January 2026) Corporate update with pipeline progress: tovecimig PFS/OS analyses on track for late Q1 2026, Phase 2 DLL4+ basket study planned post-COMPANION-002 analysis
(January 2026) Appointed Arjun Prasad as Chief Commercial Officer (ex-Servier, led 10+ oncology launches) and Cynthia Sirard, MD as Chief Medical Officer
(January 2026) Granted inducement stock options (1M shares each) to new executives at $5.17 exercise price
(December 2025) Participated in Piper Sandler 37th Annual Healthcare Conference and Evercore 8th Annual Healthcare Conference
Open the full interactive Compass Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.